Literature DB >> 25202123

MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1.

Sriganesh B Sharma1, Chen-Chung Lin2, Mark K Farrugia1, Sarah L McLaughlin3, Emily J Ellis3, Kathleen M Brundage3, Mohamad A Salkeni4, J Michael Ruppert5.   

Abstract

Despite the low prevalence of activating point mutation of RAS or RAF genes, the RAS-extracellular signal-regulated kinase (ERK) pathway is implicated in breast cancer pathogenesis. Indeed, in triple-negative breast cancer (TNBC), there is recurrent genetic alteration of pathway components. Using short hairpin RNA (shRNA) methods, we observed that the zinc finger transcription factor Krüppel-like factor 4 (KLF4) can promote RAS-ERK signaling in TNBC cells. Endogenous KLF4 bound to the promoter regions and promoted the expression of two microRNAs (miRs), miR-206 and miR-21 (i.e., miR-206/21). Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 and SPRED1. In TNBC cells, including cells with mutation of RAS, the suppression of either RASA1 or SPRED1 increased the levels of GTP-bound, wild-type RAS and activated ERK 1/2. Unlike the control cells, treatment of RASA1- or SPRED1-suppressed cells with anti-miR-206/21 had little or no impact on the level of activated ERK 1/2 or on cell proliferation and failed to suppress tumor initiation. These results identify RASA1 and SPRED1 mRNAs as latent RAS-ERK pathway suppressors that can be upregulated in tumor cells by anti-miR treatment. Consequently, KLF4-regulated miRs are important for the maintenance of RAS-ERK pathway activity in TNBC cells.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25202123      PMCID: PMC4248710          DOI: 10.1128/MCB.00480-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  97 in total

Review 1.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

2.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

3.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.

Authors:  X Yang; A T Ferguson; S J Nass; D L Phillips; K A Butash; S M Wang; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 4.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

5.  Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Authors:  K Wade Foster; Zhaoli Liu; Clinton D Nail; Xingnan Li; Thomas J Fitzgerald; Sarah K Bailey; Andra R Frost; Iuri D Louro; Tim M Townes; Andrew J Paterson; Jeffrey E Kudlow; Susan M Lobo-Ruppert; J Michael Ruppert
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

Review 6.  Ras signaling and therapies.

Authors:  Amy Young; Jesse Lyons; Abigail L Miller; Vernon T Phan; Irma Rangel Alarcón; Frank McCormick
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

7.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Authors:  Naoto Kondo; Tatsuya Toyama; Hiroshi Sugiura; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 9.  Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.

Authors:  Jacqueline Whyte; Orla Bergin; Alessandro Bianchi; Sara McNally; Finian Martin
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

View more
  29 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

2.  Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.

Authors:  Rong Tian; Tao Liu; Li Qiao; Mei Gao; Jing Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  miR-148a and miR-17-5p synergistically regulate milk TAG synthesis via PPARGC1A and PPARA in goat mammary epithelial cells.

Authors:  Zhi Chen; Jun Luo; Shuang Sun; Duoyao Cao; Huaiping Shi; Juan J Loor
Journal:  RNA Biol       Date:  2017-01-17       Impact factor: 4.652

Review 4.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

5.  Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.

Authors:  Yongzhi Yang; Wenhao Weng; Junjie Peng; Leiming Hong; Lei Yang; Yuji Toiyama; Renyuan Gao; Minfeng Liu; Mingming Yin; Cheng Pan; Hao Li; Bomin Guo; Qingchao Zhu; Qing Wei; Mary-Pat Moyer; Ping Wang; Sanjun Cai; Ajay Goel; Huanlong Qin; Yanlei Ma
Journal:  Gastroenterology       Date:  2016-11-19       Impact factor: 22.682

6.  Acute 4,4'-Methylene Diphenyl Diisocyanate Exposure-Mediated Downregulation of miR-206-3p and miR-381-3p Activates Inducible Nitric Oxide Synthase Transcription by Targeting Calcineurin/NFAT Signaling in Macrophages.

Authors:  Chen-Chung Lin; Brandon F Law; Justin M Hettick
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

7.  miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells.

Authors:  Xijia Zhu; Xishun Luo; Zhike Song; Shiyu Jiang; Xiangkai Long; Xueyuan Gao; Xinyang Xie; Laijian Zheng; Haipeng Wang
Journal:  Oncol Lett       Date:  2021-04-20       Impact factor: 2.967

Review 8.  Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses.

Authors:  Mark K Farrugia; Daniel B Vanderbilt; Mohamad A Salkeni; J Michael Ruppert
Journal:  Cancer Res       Date:  2016-03-10       Impact factor: 12.701

9.  RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.

Authors:  Rui-Li Zhang; Jun-Ping Yang; Li-Xia Peng; Li-Sheng Zheng; Ping Xie; Meng-Yao Wang; Yun Cao; Zhi-Ling Zhang; Fang-Jian Zhou; Chao-Nan Qian; Yong-Xing Bao
Journal:  Cell Cycle       Date:  2016-10-21       Impact factor: 4.534

Review 10.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.